ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026
Evaluation of PET-detected nodal upstaging and planning target volume expansion in esophageal cancer radiotherapy planning.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile 18F-fluorodeoxyglucose positron emission tomography (FDG-PET/CT) is known to influence staging, its quantitative impact on clinically meaningful target volume expansion remains incompletely characterized. We evaluated whether PET-detected nodal upstaging is associated with significant planning target volume (PTV) expansion.
methodsFifty consecutive eligible patients with esophageal cancer undergoing computed tomography (CT)- and PET-based radiotherapy planning between January 2018 and January 2022 were retrospectively analyzed, with no predefined target sample size. Clinically significant PTV expansion was predefined as a > 10% increase from CT-based to PET-based planning. Associations between PET-detected nodal upstaging and PTV expansion were evaluated using Fisher's exact test, logistic regression, receiver operating characteristic (ROC) analysis, and nonparametric testing. Given the limited number of events, a parsimonious multivariable model and threshold sensitivity analyses were additionally performed.
resultsPatients with nodal upstaging had a significantly higher risk of > 10% PTV expansion (48.0% vs. 16.7%; absolute risk difference 31.3%, 95% CI 6.7-55.9%; p = 0.032). The median percent PTV change was significantly higher in patients with nodal upstaging (9.49% vs. 0.31%; Wilcoxon p < 0.001). In a parsimonious multivariable model adjusting for tumor length, nodal upstaging remained independently associated with clinically significant PTV expansion (odds ratio (OR) 4.38, 95% confidence interval (CI) 1.12-17.10; p = 0.033). Model discrimination was acceptable (area under the curve (AUC) 0.7254), with stable performance on bootstrap internal validation (bootstrap mean AUC 0.733). Sensitivity analyses using alternative expansion thresholds (> 5%, > 10%, and > 15%) demonstrated directionally consistent associations. Patients meeting the PTV expansion threshold also demonstrated significantly greater increases in lung dose-volume burden (mean lung dose, and lung volumes receiving 5 Gy and 20 Gy; all p < 0.001) in paired dosimetric comparison, supporting the clinical relevance of this threshold.
conclusionDuring esophageal cancer radiotherapy planning, PET-detected nodal upstaging was independently associated with clinically meaningful target volume expansion. The association was consistent across alternative expansion thresholds and in bootstrap internal validation, and a paired lung dose-volume comparison indicated that the expansion threshold corresponds to a measurable increase in lung dose burden.
Indexed as
Identifiers
42860437What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.